Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom
Autor
Otero-Losada, Matilde
Petrovsky, Nikolai
Alami, Abdallah
Crispo, James A.
Mattison, Donald
Capani, Francisco
Goetz, Christopher
Krewski, Daniel
Perez-Lloret, Santiago
Resumen
Background: Information on neurological and psychiatric adverse events following immunization (AEFIs) with COVID-19 vaccines is limited. Research design & methods: We examined and compared neurological and psychiatric AEFIS reports related to BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccines and recorded in the United Kingdom Medicines and Healthcare products Regulatory Agency between 9 December 2020 and 30 June 2021. Results: As of 30 June 2021, 46.1 million doses of ChAdOx1 and 30.3 million doses of BNT162b2 had been administered. The most frequently reported AEFI was headache with 1,686 and 575 cases per million doses of ChAdOx1 and BNT162b2, respectively. AEFIs more frequently reported after CHAdOx1 compared with BNT162b2 vaccination were Guillain-Barré syndrome (OR, 95% CI = 2.53, 1.82–3.51), freezing (6.66, 3.12–14.22), cluster headache (1.53, 1.28–1.84), migraine (1.23,1.17–1.30), postural dizziness (1.24,1.13–1.37), tremor (2.86, 2.68–3.05), headache (1.40, 1.38–1.43), paresthesia (1.11, 1.06–1.16), delirium (1.85, 1.45–2.36), hallucination (2.20, 1.82–2.66), poor quality sleep (1.53, 1.26–1.85), and nervousness (1.54, 1.26–1.89) Reactions less frequently reported with ChAdOx1 than with BNT162b2 were Bell’s palsy (0.47, 0.41–0.55), anosmia (0.58, 0.47–0.71), facial paralysis (0.35, 0.29–0.41), dysgeusia (0.68, 0.62–0.73), presyncope (0.48, 0.42–0.55), syncope (0.63, 0.58–0.67), and anxiety (0.75 (0.67–0.85). Conclusion: Neurological and psychiatric AEFIs were relatively infrequent, but each vaccine was associated with a distinctive toxic profile. © 2022 Informa UK Limited, trading as Taylor & Francis Group.
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Article
Parkinson's Disease in the Era of a Novel Respiratory Virus Pandemic (2020)
Otero-Losada, Matilde; Kobiec, Tamara; Udovin, Lucas Daniel; Chevalier, Guenson; Quarracino, Cecilia; Menéndez Maissonave, Camila; Bordet, Sofia; Capani, Francisco; Perez-Lloret, Santiago (Frontiers Media S.A., 2020-09-11) -
Article
Genetics of Neurogenic Orthostatic Hypotension in Parkinson’s Disease, Results from a Cross-Sectional In Silico Study (2024)
Chevalier, Guenson; Udovin, Lucas; Otero-Losada, Matilde; Bordet, Sofia; Capani, Francisco; Luo, Sheng; Goetz, Christopher G.; Perez-Lloret, Santiago (MDPI, 2023)The genetic basis of Neurogenic Orthostatic Hypotension (NOH) in Parkinson’s disease (PD) has been inadequately explored. In a cross-sectional study, we examined the association between NOH and PD-related single-nucleotide ... -
Article
The Renin–Angiotensin System Modulates Dopaminergic Neurotransmission: A New Player on the Scene (2021)
Kobiec, Tamara; Otero-Losada, Matilde; Chevalier, Guenson; Udovin, Lucas Daniel; Bordet, Sofía; Menéndez-Maissonave, Camila; Capani, Francisco; Perez-Lloret, Santiago (Frontiers Media S.A., 2021-04-22)Parkinson’s disease (PD) is an extrapyramidal disorder characterized by neuronal degeneration in several regions of the peripheral and central nervous systems. It is the second most frequent neurodegenerative disease after ...